Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers analyzed skin samples from Dorper sheep to identify 395 differentially expressed long non-coding RNAs (lncRNAs) linked to hair follicle growth phases, suggesting these lncRNAs may play a role in the regulation of hair shedding through pathways like estrogen and PI3K-Akt signaling.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This paper describes Grahams Little Piccardi Lassueur Syndrome, a rare type of Lichen Planopilaris that causes different types of alopecia and distinctive skin papules, primarily affecting females aged 40 to 70, and notes the current challenges in treatment options, particularly once scarring occurs.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

This study found that higher Lnk expression in PCOS patients may contribute to insulin resistance by inhibiting insulin signaling pathways.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This study found that low-level laser therapy effectively reduced relapse rates, while functional appliances did not; combining them offered no additional benefits.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This article discusses the SLICC's revision and validation of the ACR SLE classification criteria to enhance clinical relevance and integrate recent immunological insights, but does not report new clinical results.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

The LTF gene may help predict and manage nonspecific orbital inflammation.

This case report details a 17-year-old girl with systemic lupus erythematosus and recurrent infections linked to a complete isolated Clq deficiency.

This study identified biallelic variants in the LSS gene as a possible genetic cause of palmoplantar keratoderma-congenital alopecia syndrome type 2, highlighting the role of cholesterol synthesis in skin cornification.

This study suggests that Arabs with systemic lupus erythematosus in Dubai show similar clinical features to patients from other Arab and Western countries, with a notable prevalence of positive anti-Ro antibodies.

An 8-year-old girl developed a rare skin condition in a linear pattern on one side of her body after a lung infection, which improved with treatment.

This article discusses revised SLE classification criteria by the SLICC and reports no new research results.

In this study, baseline neutrophil-to-lymphocyte ratio (NLR) was associated with predicting early trichoscopic response in patients undergoing PRP-based treatment for non-scarring alopecia.

This clinical letter identifies Rothmund-Thomson syndrome type 2 as a rare cause of chronic wounds, but provides no new experimental findings.

This case report describes a woman in her 30s diagnosed with systemic lupus erythematosus, characterized by alopecia, arthritis, photosensitivity, and skin rashes, confirmed through positive serology.

This study examined medical comorbidities and medications among women with vulvar lichen sclerosus, contributing insights for comprehensive treatment strategies, but does not report new clinical results.

This review covers the development and validation of classification criteria for systemic lupus erythematosus, detailing the changes from the 1982 ACR criteria to the 2012 SLICC criteria, and reports no new results.

In this case report, a 33-year-old male with symptoms resembling Neuromyelitis Optica was treated with 10 mg biotin daily, which may reverse certain ophthalmologic and myelopathy findings. The researchers emphasize the need for further research on biotinidase deficiency in patients misdiagnosed with similar conditions.

Loose anagen hair syndrome in children may improve with age, but treatment results vary.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

A Saudi girl was diagnosed with Loose Anagen Hair Syndrome, a rare condition causing easy hair loss without scarring.

This study found that the Cutaneous Lupus Disease Area and Severity Index (CLASI) is correlated with both physician-assessed and patient-reported outcomes in cutaneous lupus erythematosus, particularly highlighting concerns about body image in visible areas.